Bupropion May Benefit Patients with Diabetic Retinopathy

A study presented at the ARVO 2026 meeting suggests that bupropion (Wellbutrin) may slow the
progression of diabetic retinopathy (DR) in patients with type 2 diabetes. Researchers believe the drug’s ability to reduce systemic inflammatory cytokines contributes to these protective ocular effects.

Key Study Results

Using the Chang Gung Research Database in Taiwan, researchers compared 1,574 adults with preexisting DR. Patients taking bupropion showed significantly better outcomes than non-users:

  • Complication Reduction: Bupropion users had a 6.9% incidence of major DR complications (like retinal detachment or vitreous hemorrhage) compared to 12.8% in the control group.

  • Fewer Interventions: There was a substantial drop in the need for retinal lasers, vitrectomies, or intravitreal injections.

  • Broad Ocular Benefits: The data also indicated a lower risk of developing cataracts and glaucoma, as well as a reduced need for intraocular pressure-lowering medications.

Conclusion

While traditionally used for depression or smoking cessation, bupropion may offer a novel secondary benefit by protecting the vision of diabetic patients.

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

Keratoconus and Inflammatory Skin Conditions

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH